Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 1, 2009, Pages 288-295

  Greiner, S ^a   Kadow Romacker, A ^a   Schmidmaier, G ^a   Wildemann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Coating; Coculture; OPG; Osteoblast; Osteoclast; RANKL; Zoledronic acid

Indexed keywords

COCULTURE; OPG; OSTEOCLAST; RANKL; ZOLEDRONIC ACID;

ACIDS; CELL MEMBRANES; CHELATION; COATINGS; CONCENTRATION (PROCESS); SELF ASSEMBLY;

OSTEOBLASTS;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; POLYLACTIDE; PROCOLLAGEN; ZOLEDRONIC ACID;

ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DENTIN; DRUG COATING; DRUG EXPOSURE; HUMAN; HUMAN CELL; IMPLANT; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN SYNTHESIS;

ACID PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL COUNT; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; COCULTURE TECHNIQUES; COLLAGEN TYPE I; DIPHOSPHONATES; HUMANS; IMIDAZOLES; ISOENZYMES; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; POLYESTERS; RANK LIGAND;

EID: 70349100112     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32245     Document Type: Article

References (37)

1. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-461. (Pubitemid 20070052)
2. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998;22:455-461. (Pubitemid 28226858)
3. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998;27:38-41. (Pubitemid 28116468)
4. Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 2007;80:769-775. (Pubitemid 46309981)
5. Greiner S, Kadow-Romacker A, Wildemann B, Schwabe P, Schmidmaier G. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res A 2007;83:1184-1191. (Pubitemid 350231781)
6. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-1935. (Pubitemid 19148862)
7. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999;25:447-452. (Pubitemid 29424238)
8. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007. (Pubitemid 30839630)
9. Tokuda H, Kozawa O, Harada A, Uematsu T. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: Inhibition of phospholipase D activation in MC3T3-E1 cells. J Cell Biochem 1998;69:252-259. (Pubitemid 28227702)
10. van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002;30:64-70.
11. Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, Kiyoki M. Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int 1998;63:143-147. (Pubitemid 28347689)
12. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323. (Pubitemid 29061638)
13. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176. (Pubitemid 28180851)
14. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545. (Pubitemid 29168945)
15. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508.
16. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-4389 (Pubitemid 30666099)
17. Evans CE. Bisphosphonates modulate the effect of macrophage- like cells on osteoblast. Int J Biochem Cell Biol 2002;34:554-563.
18. Horowitz SM, Gonzales JB. Inflammatory response to implant particulates in a macrophage/osteoblast coculture model. Calcif Tissue Int 1996;59:392-396.
19. Nicolin V, Baldini G, Bareggi R, Zweyer M, Zauli G, Vaccarezza M, Narducci P. Morphological features of osteoclasts derived from a co-culture system. J Mol Histol 2006;37:171-177.
20. Nicolin V, Bareggi R, Baldini G, Bortul R, Martinelli B, Narducci P. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures. Acta Histochem 2007;109:397-402. (Pubitemid 47496173)
21. Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K. Nitrogen-containing bisphosphonate. YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 2005;328:91-97.
22. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest 2002;20 (Suppl 2):45-54.
23. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
24. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-540. (Pubitemid 44631677)
25. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: Current issues. J Support Oncol 2007;5:475-482.
26. Li J, Mori S, Mashiba T, Kaji Y, Taki M, Komatsubara S, Kawanishi J, Norimatsu H. Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage. Bone 1998;23:459-463. (Pubitemid 28470616)
27. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661. (Pubitemid 34815869)
28. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
29. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
30. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686. (Pubitemid 34687400)
31. Adolphson P, Abbaszadegan H, Boden H, Salemyr M, Henriques T. Clodronate increases mineralization of callus after Colles' fracture: A randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 2000;71:195-200. (Pubitemid 30611747)
32. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res 2005;23:1029-1034. (Pubitemid 41245425)
33. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007;22:867-876. (Pubitemid 351339747)
34. Goodship AE, Walker PC, McNally D, Chambers T, Green JR. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994;5 (Suppl 7):S53-S55. (Pubitemid 24382836)
35. Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 2001;16:429-436. (Pubitemid 32173356)
36. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 1999;14:969-979. (Pubitemid 29262892)
37. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.